Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study—Asian Subgroup Analysis

INTRODUCTION: The primary analysis of a global phase 3 study that evaluated the efficacy and safety of denosumab versus zoledronic acid for preventing skeletal-related events (SREs) in adults with newly diagnosed multiple myeloma (MM) indicated that denosumab was noninferior to zoledronic acid for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Shang-Yi, Yoon, Sung-Soo, Shimizu, Kazuyuki, Chng, Wee Joo, Chang, Cheng-Shyong, Wong, Raymond Siu-Ming, Gao, Seasea, Wang, Yang, Gordon, Steve W., Glennane, Anthony, Min, Chang-Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467415/
https://www.ncbi.nlm.nih.gov/pubmed/32524500
http://dx.doi.org/10.1007/s12325-020-01395-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467415/
https://www.ncbi.nlm.nih.gov/pubmed/32524500
http://dx.doi.org/10.1007/s12325-020-01395-x

Ejemplares similares